Historical record - last NADAC effective date: 6/19/2019
Product Information
THERAFLU NT SEVERE CLD-CGH PKT is a brand product labeled by Haleon US Holdings LLC, priced at $0.9074 per EA under NDC 00067791806. Its NADAC has been published 247 times since Sep 23, 2015.
Strength
650; 25; 10 mg/237mL; mg/237mL; mg/237mL
Manufacturer
Haleon US Holdings LLCNDC
00067791806
Classification
Brand
Dosage Form
POWDER, FOR SOLUTION
Route
ORAL
Effective Date
6/19/2019
Approval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
7/1/2014
Pharmacological Classes
Price Statistics
The NADAC for THERAFLU NT SEVERE CLD-CGH PKT has been published 247 times since Sep 23, 2015, and over the history we have for it it has risen 10.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9074 per EA |
|---|---|
| All-time high | $0.9074 (Jun 10, 2020) |
| All-time low | $0.8250 (Sep 23, 2015) |
| Median price | $0.8706 |
| Average price | $0.8674 |
| Largest weekly change | +9.7% (Oct 21, 2015) |
| Weeks tracked | 247 |
| Tracking since | Sep 23, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+10.0%
Last surveyed Jun 10, 2020 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PHENYLEPHRINE HCL market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Haleon US Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PHENYLEPHRINE HCL market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THERAFLU NT SEVERE CLD-CGH PKT?
The current National Average Drug Acquisition Cost (NADAC) for THERAFLU NT SEVERE CLD-CGH PKT, manufactured by Haleon US Holdings LLC, is $0.9074 per EA (NDC 00067791806), effective Jun 10, 2020.
How has the price of THERAFLU NT SEVERE CLD-CGH PKT changed over time?
Over the history we have for it, the NADAC for THERAFLU NT SEVERE CLD-CGH PKT has risen 10.0%. It has been tracked across 247 weekly CMS publications since Sep 23, 2015.
What are the highest and lowest recorded NADAC prices for THERAFLU NT SEVERE CLD-CGH PKT?
Since Sep 23, 2015, the NADAC for THERAFLU NT SEVERE CLD-CGH PKT has ranged from a low of $0.8250 (Sep 23, 2015) to a high of $0.9074 (Jun 10, 2020), with a median of $0.8706 per EA.
Are there cheaper alternatives to THERAFLU NT SEVERE CLD-CGH PKT?
No other NADAC-published product currently shares the active ingredient and strength of THERAFLU NT SEVERE CLD-CGH PKT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures THERAFLU NT SEVERE CLD-CGH PKT?
THERAFLU NT SEVERE CLD-CGH PKT (NDC 00067791806) is labeled by Haleon US Holdings LLC, and CMS classifies it as a brand product.